Spinal Muscular Atrophy (SMA) Treatment Market Report

Global Spinal Muscular Atrophy (SMA) Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 09, 2022
  • PAGES：139
  • REPORT CODE：GMM870314
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Spinal Muscular Atrophy (SMA) Treatment market report explains the definition, types, applications, major countries, and major players of the Spinal Muscular Atrophy (SMA) Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Isis Pharmaceuticals

    • Pfizer

    • Boehringer Ingelheim

    • Regeneron Pharmaceuticals

    • Biogen Idec

    • F Hoffmann-La Roche

    By Type:

    • Type I Spinal Muscular Atrophy (SMA)

    • Type II Spinal Muscular Atrophy (SMA)

    • Type III Spinal Muscular Atrophy (SMA)

    By End-User:

    • Hospitals

    • Ambulatory Surgical Centers

    • Diagnostic Centers

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Spinal Muscular Atrophy (SMA) Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Spinal Muscular Atrophy (SMA) Treatment Outlook to 2028- Original Forecasts

    • 2.2 Spinal Muscular Atrophy (SMA) Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Spinal Muscular Atrophy (SMA) Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Spinal Muscular Atrophy (SMA) Treatment Market- Recent Developments

    • 6.1 Spinal Muscular Atrophy (SMA) Treatment Market News and Developments

    • 6.2 Spinal Muscular Atrophy (SMA) Treatment Market Deals Landscape

    7 Spinal Muscular Atrophy (SMA) Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Spinal Muscular Atrophy (SMA) Treatment Key Raw Materials

    • 7.2 Spinal Muscular Atrophy (SMA) Treatment Price Trend of Key Raw Materials

    • 7.3 Spinal Muscular Atrophy (SMA) Treatment Key Suppliers of Raw Materials

    • 7.4 Spinal Muscular Atrophy (SMA) Treatment Market Concentration Rate of Raw Materials

    • 7.5 Spinal Muscular Atrophy (SMA) Treatment Cost Structure Analysis

      • 7.5.1 Spinal Muscular Atrophy (SMA) Treatment Raw Materials Analysis

      • 7.5.2 Spinal Muscular Atrophy (SMA) Treatment Labor Cost Analysis

      • 7.5.3 Spinal Muscular Atrophy (SMA) Treatment Manufacturing Expenses Analysis

    8 Global Spinal Muscular Atrophy (SMA) Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Spinal Muscular Atrophy (SMA) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Spinal Muscular Atrophy (SMA) Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Spinal Muscular Atrophy (SMA) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Type I Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Type II Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Type III Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)

    • 9.2 Global Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Diagnostic Centers Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Spinal Muscular Atrophy (SMA) Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.2.2 Canada Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.2 UK Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.3 Spain Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.5 France Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.6 Italy Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.8 Finland Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.9 Norway Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.11 Poland Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.12 Russia Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.2 Japan Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.3 India Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.3 Chile Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.6 Peru Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.6.3 Oman Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Spinal Muscular Atrophy (SMA) Treatment Consumption (2017-2022)

    11 Global Spinal Muscular Atrophy (SMA) Treatment Competitive Analysis

    • 11.1 Isis Pharmaceuticals

      • 11.1.1 Isis Pharmaceuticals Company Details

      • 11.1.2 Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

      • 11.1.4 Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Pfizer

      • 11.2.1 Pfizer Company Details

      • 11.2.2 Pfizer Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Pfizer Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

      • 11.2.4 Pfizer Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Boehringer Ingelheim

      • 11.3.1 Boehringer Ingelheim Company Details

      • 11.3.2 Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

      • 11.3.4 Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Regeneron Pharmaceuticals

      • 11.4.1 Regeneron Pharmaceuticals Company Details

      • 11.4.2 Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

      • 11.4.4 Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Biogen Idec

      • 11.5.1 Biogen Idec Company Details

      • 11.5.2 Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

      • 11.5.4 Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 F Hoffmann-La Roche

      • 11.6.1 F Hoffmann-La Roche Company Details

      • 11.6.2 F Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 F Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

      • 11.6.4 F Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    12 Global Spinal Muscular Atrophy (SMA) Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Type I Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Type II Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Type III Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Diagnostic Centers Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Spinal Muscular Atrophy (SMA) Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Spinal Muscular Atrophy (SMA) Treatment

    • Figure of Spinal Muscular Atrophy (SMA) Treatment Picture

    • Table Global Spinal Muscular Atrophy (SMA) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Spinal Muscular Atrophy (SMA) Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Type I Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)

    • Figure Global Type II Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)

    • Figure Global Type III Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Diagnostic Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Table North America Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure United States Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure Germany Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure China Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure Brazil Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Spinal Muscular Atrophy (SMA) Treatment Consumption by Country (2017-2022)

    • Figure Australia Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Spinal Muscular Atrophy (SMA) Treatment Consumption and Growth Rate (2017-2022)

    • Table Isis Pharmaceuticals Company Details

    • Table Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

    • Table Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

    • Table Pfizer Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

    • Table Boehringer Ingelheim Company Details

    • Table Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

    • Table Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

    • Table Regeneron Pharmaceuticals Company Details

    • Table Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

    • Table Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

    • Table Biogen Idec Company Details

    • Table Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

    • Table Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

    • Table F Hoffmann-La Roche Company Details

    • Table F Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Main Business and Markets Served

    • Table F Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Product Portfolio

    • Figure Global Type I Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type II Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type III Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Diagnostic Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Spinal Muscular Atrophy (SMA) Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US